We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Bead Spheres Help Occlude Hypervascular Tumors

By HospiMedica International staff writers
Posted on 01 Jul 2014
Print article
Innovative bioresorbable miniscule gelatin beads offer a new embolization treatment option when a permanent embolic agent is not desired.

The Gel-Bead embolization spheres are precisely sized gelatin beads that are inserted into the hypervascular tumor using a delivery catheter. The spheres form an artificial clot that is resorbed over time, providing physicians with an alternative to currently used microspheres, polyvinyl alcohol (PVA), particles, and gelatin foam slurries. The spheres eventually undergo complete degradation, beginning at 4 weeks, with some spheres still present at 12 weeks. Studies showed that the majority of treated vessels showed no signs of recanalization at 12 weeks.

The Gel-Beads are supplied in 20 mL syringes, each containing 1 mL of gelatin spheres suspended in 5 mL of saline, and are available in four sizes of sphere diameter (100–300 µm, 300–500 µm, 500–700V, and 700–1,000 µm), each identified by a different colored syringe plunger. The spheres are manufactured using an emulsion system and cross-linked with glutaraldehyde. The Gel-Bead embolization spheres are a product of Vascular Solutions (Minneapolis, MN, USA), and have been approved by the US Food and Drug Administration (FDA).

“We are very pleased to announce the launch of Gel-Bead, our latest offering to leverage our biologics expertise in the field of embolization,” said Howard Root, CEO of Vascular Solutions. “With the launch of Gel-Bead, we offer the additional configuration of uniform spheres designed for smooth embolic delivery and predictable distribution, all at a very economical price. Over time, we plan to continue to add to our embolization products with future versions designed to meet specific therapeutic needs.”

Related Links:

Vascular Solutions 


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Needlefree Closed System Transfer Device
ChemoClave

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.